Recent insights into the biology of macrophage scavenger receptors

Journal of Lipid Research

Volumn 46, Issue 1, 2005, Pages 11-20

  Greaves, David R ^a   Gordon, Siamon ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Atherosclerosis; Innate immunity; Oxidized low density lipoprotein

Indexed keywords

CD163 ANTIGEN; CD36 ANTIGEN; CD68 ANTIGEN; CELL SURFACE RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PHOSPHATIDYLSERINE RECEPTOR; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR BI; STABILIN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; LIGAND; LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DENDRITIC CELL; FOAM CELL; IMMUNE SYSTEM; INTERNALIZATION; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VASCULAR SMOOTH MUSCLE; ANIMAL; HUMAN; IMMUNITY; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; FOAM CELLS; HUMANS; IMMUNITY; LIGANDS; LIPOPROTEINS, LDL; MACROPHAGES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, SCAVENGER; SCAVENGER RECEPTORS, CLASS A;

EID: 11244319578     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.R400011-JLR200     Document Type: Review

References (129)

1. Faggiotto, A., R. Ross, and L. Harker. 1984. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis. 4: 323-340.
2. Faggiotto, A., and R. Ross. 1984. Studies of hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. Arteriosclerosis. 4: 341-356.
3. Glass, C. K., and J. L. Witztum. 2001. Atherosclerosis. The road ahead. Cell. 104: 503-516.
4. Li, A. C., and C. K. Glass. 2002. The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 8: 1235-1242.
5. Goldstein, J. L., Y. K. Ho, S. K. Basu, and M. S. Brown. 1979. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA. 76: 333-337.
6. Brown, M. S., and J. L. Goldstein. 1983. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 52: 223-261.
7. Krieger, M., S. Acton, J. Ashkenas, A. Pearson, M. Penman, and D. Resnick. 1993. Molecular flypaper, host defense, and atherosclerosis. Structure, binding properties, and functions of macrophage scavenger receptors. J. Biol. Chem. 268: 4569-4572.
8. Krieger, M., and J. Herz. 1994. Structures and functions of multi-ligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu. Rev. Biochem. 63: 601-637.
9. Soccio, R. E., and J. L. Breslow. 2004. Intracellular cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 24: 1150-1160.
10. Tall, A. R., and N. Wang. 2000. Tangier disease as a test of the reverse cholesterol transport hypothesis. J. Clin. Invest. 106: 1205-1207.
11. Ory, D. S. 2004. Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home? Circ. Res. 95: 660-670.
12. Tontonoz, P., L. Nagy, J. G. Alvarez, V. A. Thomazy, and R. M. Evans. 1998. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93: 241-252.
13. Nagy, L., P. Tontonoz, J. G. Alvarez, H. Chen, and R. M. Evans. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 93: 229-240.
14. Ricote, M., A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass. 1998. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 391: 79-82.
15. Jiang, C., A. T. Ting, and B. Seed. 1998. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 391: 82-86.
16. Welch, J. S., M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass. 2003. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. USA. 100: 6712-6717.
17. Ricote, M., A. F. Valledor, and C. K. Glass. 2004. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24: 230-239.
18. Li, A. C., K. K. Brown, M. J. Silvestre, T. M. Willson, W. Palinski, and C. K. Glass. 2000. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106: 523-531.
19. Joseph, S. B., and P. Tontonoz. 2003. LXRs: new therapeutic targets in atherosclerosis? Curr. Opin. Pharmacol. 3: 192-197.
20. Jaakkola, O., O. P. Kallioniemi, and T. Nikkari. 1988. Lipoprotein uptake in primary cell cultures of rabbit atherosclerotic lesions. A fluorescence microscopic and flow cytometric study. Atherosclerosis. 69: 257-268.
21. Jaakkola, O., S. Yla-Herttuala, T. Sarkioja, and T. Nikkari. 1989. Macrophage foam cells from human aortic fatty streaks take up beta-VLDL and acetylated LDL in primary culture. Atherosclerosis. 79: 173-182.
22. Pitas, R. E., A. Friera, J. McGuire, and S. Dejager. 1992. Further characterization of the acetyl LDL (scavenger) receptor expressed by rabbit smooth muscle cells and fibroblasts. Arterioscler. Thromb. 12: 1235-1244.
23. Gong, Q., and R. E. Pitas. 1995. Synergistic effects of growth factors on the regulation of smooth muscle cell scavenger receptor activity. J. Biol. Chem. 270: 21672-21678.
24. Zhou, Y. F., E. Guetta, Z. X. Yu, T. Finkel, and S. E. Epstein. 1996. Human cytomegalovirus increases modified low density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells. J. Clin. Invest. 98: 2129-2138.
25. Li, S., S. Sims, Y. Jiao, L. H. Chow, and J. G. Pickering. 1999. Evidence from a novel human cell clone that adult vascular smooth muscle cells can convert reversibly between noncontractile and contractile phenotypes. Circ. Res. 85: 338-348.
26. Li, S., Y. S. Fan, L. H. Chow, C. Van Den Diepstraten, E. van Der Veer, S. M. Sims, and J. G. Pickering. 2001. Innate diversity of adult human arterial smooth muscle cells: cloning of distinct subtypes from the internal thoracic artery. Circ. Res. 89: 517-525.
27. Argmann, C. A., C. G. Sawyez, S. Li, Z. Nong, R.A. Hegele, J. G. Pickering, and M. W. Huff. 2004. Human smooth muscle cell sub-populations differentially accumulate cholesteryl ester when exposed to native and oxidized lipoproteins. Arterioscler. Thromb. Vasc. Biol. 24: 1290-1296.
28. Stolle, K., B. Weitkamp, J. Rauterberg, S. Lorkowski, and P. Cullen. 2004. Laser microdissection-based analysis of mRNA expression in human coronary arteries with intimal thickening. J. Histochem. Cytochem. 52: 1511-1518.
29. Rong, J. X., M. Shapiro, E. Trogan, and E. A. Fisher. 2003. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc. Natl. Acad. Sci. USA. 100: 13531-13536.
30. Van Berkel, T. J., M. Van Eck, N. Herijgers, K. Fluiter, and S. Nion. 2000. Scavenger receptor classes A and B. Their roles in atherogenesis and the metabolism of modified LDL and HDL. Ann. N.Y. Acad. Sci. 902: 113-127.
31. Peiser, L., and S. Gordon. 2001. The function of scavenger receptors expressed by macrophages and their role in the regulation of inflammation. Microbes Infect. 3: 149-159.
32. Peiser, L., S. Mukhopadhyay, and S. Gordon. 2002. Scavenger receptors in innate immunity. Curr. Opin. Immunol. 14: 123-128.
33. Febbraio, M., D. P. Hajjar, and R. L. Silverstein. 2001. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108: 785-91.
34. Endemann, G., L. W. Stanton, K. S. Madden, C. M. Bryant, R. T. White, and A. A. Protter. 1993. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268: 11811-11816.
35. Febbraio, M., N. A. Abumrad, D. P. Hajjar, K. Sharma, W. Cheng, S. F. Pearce, and R. L. Silverstein. 1999. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 274: 19055-19062.
36. Febbraio, M., E. A. Podrez, J. D. Smith, D. P. Hajjar, S. L. Hazen, H. F. Hoff, K. Sharma, and R. L. Silverstein. 2000. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105: 1049-1056.
37. Febbraio, M., E. Guy, and R. L. Silverstein. 2004. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. In press.
38. Horkko, S., D. A. Bird, E. Miller, H. Itabe, N. Leitinger, G. Subbanagounder, J. A. Berliner, P. Friedman, E. A. Dennis, L. K. Curtiss, W. Palinski, and J. L. Witztum. 1999. Monoclonal auto-antibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103: 117-128.
39. Boullier, A., K. L. Gillotte, S. Horkko, S. R. Green, P. Friedman, E. A. Dennis, J. L. Witztum, D. Steinberg, and O. Quehenberger. 2000. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J. Biol. Chem. 275: 9163-9169.
40. Gillotte, K. L., S. Horkko, J. L. Witztum, and D. Steinberg. 2000. Oxidized phospholipids, linked to apolipoprotein B of oxidized LDL, are ligands for macrophage scavenger receptors. J. Lipid Res. 41: 824-833.
41. Podrez, E. A., E. Poliakov, Z. Shen, R. Zhang, Y. Deng, M. Sun, P. J. Finton, L. Shan, M. Febbraio, D. P. Hajjar, R. L. Silverstein, H. F. Hoff, R. G. Salomon, and S. L. Hazen. 2002. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277: 38517-38523.
42. Podrez, E. A., E. Poliakov, Z. Shen, R. Zhang, Y. Deng, M. Sun, P. J. Finton, L. Shan, B. Gugiu, P. L. Fox, H. F. Hoff, R. G. Salomon, and S. L. Hazen. 2002. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 277: 38503-38516.
43. Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392: 86-89.
44. Acton, S. L., P. E. Scherer, H. F. Lodish, and M. Krieger. 1994. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 269: 21003-21009.
45. Webb, N. R., P. M. Connell, G. A. Graf, E. J. Smart, W. J. de Villiers, F. C. de Beer, and D. R. van der Westhuyzen. 1998. SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells. J. Biol. Chem. 273: 15241-15248.
46. Webb, N. R., W. J. de Villiers, P. M. Connell, F. C. de Beer, and D. R. van der Westhuyzen. 1997. Alternative forms of the scavenger receptor BI (SR-BI). J. Lipid Res. 38: 1490-1495.
47. Acton, S., A. Rigotti, K. T. Landschulz, S. Xu, H. H. Hobbs, and M. Krieger. 1996. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 271: 518-520.
48. Kocher, O., A. Yesilaltay, C. Cirovic, R. Pal, A. Rigotti, and M. Krieger. 2003. Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of the high density lipoprotein receptor scavenger receptor class B type I and altered lipoprotein metabolism. J. Biol. Chem. 278: 52820-52825.
49. Silver, D. L. 2002. A carboxyl-terminal PDZ-interacting domain of scavenger receptor B, type I is essential for cell surface expression in liver. J. Biol. Chem. 277: 34042-34047.
50. Silver, D. L., N. Wang, and S. Vogel. 2003. Identification of small PDZK1-associated protein, DD96/MAP17, as a regulator of PDZK1 and plasma high density lipoprotein levels. J. Biol. Chem. 278: 28528-28532.
51. Arai, T., N. Wang, M. Bezouevski, C. Welch, and A. R. Tall. 1999. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J. Biol. Chem. 274: 2366-2371.
52. Kozarsky, K. F., M. H. Donahee, J. M. Glick, M. Krieger, and D. J. Rader. 2000. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 20: 721-727.
53. Braun, A., B. L. Trigatti, M. J. Post, K. Sato, M. Simons, J. M. Edelberg, R. D. Rosenberg, M. Schrenzel, and M. Krieger. 2002. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ. Res. 90: 270-276.
54. Braun, A., S. Zhang, H. E. Miettinen, S. Ebrahim, T. M. Holm, E. Vasile, M. J. Post, D. M. Yoerger, M. H. Picard, J. L. Krieger, N. C. Andrews, M. Simons, and M. Krieger. 2003. Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc. Natl. Acad. Sci. USA. 100: 7283-7288.
55. Covey, S. D., M. Krieger, W. Wang, M. Penman, and B. L. Trigatti. 2003. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler. Thromb. Vasc. Biol. 23: 1589-1594.
56. Zhang, W., P. G. Yancey, Y. R. Su, V. R. Babaev, Y. Zhang, S. Fazio, and M. F. Linton. 2003. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation. 108: 2258-2263.
57. Francone, O. L. 2003. SR-BI: a new player in an old game. Arterioscler. Thromb. Vasc. Biol. 23: 1486-1487.
58. Kodama, T., M. Freeman, L. Rohrer, J. Zabrecky, P. Matsudaira, and M. Krieger. 1990. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature. 343: 531-535.
59. Suzuki, H., Y. Kurihara, M. Takeya, N. Kamada, M. Kataoka, K. Jishage, O. Ueda, H. Sakaguchi, T. Higashi, T. Suzuki, Y. Takashima, Y. Kawabe, O. Cynshi, Y. Wada, M. Honda, H. Kurihara, H. Aburatani, T. Doi, A. Matsumoto, S. Azuma, T. Noda, Y. Toyoda, H. Itakura, Y. Yazaki, and T. Kodama. 1997. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 386: 292-296.
60. Penman, M., A. Lux, N. J. Freedman, L. Rohrer, Y. Ekkel, H. McKinstry, D. Resnick, and M. Krieger. 1991. The type I and type II bovine scavenger receptors expressed in Chinese hamster ovary cells are trimeric proteins with collagenous triple helical domains comprising noncovalently associated monomers and Cys83-disulfide-linked dimers. J. Biol. Chem. 266: 23985-23993.
61. Resnick, D., A. Pearson, and M. Krieger. 1994. The SRCR super-family: a family reminiscent of the Ig superfamily. Trends Biochem. Sci. 19: 5-8.
62. Sarrias, M. R., J. Gronland, O. Padilla, J. Madsen, U. Holmskov, and F. Lozano. 2004. The scavenger receptor cysteine-rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. Crit. Rev. Immunol. 24: 1-37.
63. Gough, P. J., D. R. Greaves, and S. Gordon. 1998. A naturally occurring isoform of the human macrophage scavenger receptor (SR-A) gene generated by alternative splicing blocks modified LDL uptake. J. Lipid Res. 39: 531-543.
64. Gough, P. J., D. R. Greaves, H. Suzuki, T. Hakkinen, M. O. Hiltunen, M. Turunen, S. Y. Herttuala, T. Kodama, and S. Gordon. 1999. Analysis of macrophage scavenger receptor (SR-A) expression in human aortic atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 19: 461-471.
65. Tomokiyo, R., K. Jinnouchi, M. Honda, Y. Wada, N. Hanada, T. Hiraoka, H. Suzuki, T. Kodama, K. Takahashi, and M. Takeya. 2002. Production, characterization, and interspecies reactivities of monoclonal antibodies against human class A macrophage scavenger receptors. Atherosclerosis. 161: 123-132.
66. Suzuki, H., Y. Kurihara, M. Takeya, N. Kamada, M. Kataoka, K. Jishage, O. Ueda, H. Sakaguchi, T. Higashi, T. Suzuki, Y. Takashima, Y. Kawabe, O. Cynshi, Y. Wada, M. Honda, H. Kurihara, H. Aburatani, T. Doi, A. Matsumoto, S. Azuma, T. Noda, Y. Toyoda, H. Itakura, Y. Yazaki, T. Kodama. 1997. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 386: 292-296.
67. Babaev, V. R., L. A. Cleaves, K. J. Carter, H. Suzuki, T. Kodama, S. Fazio, and M. F. Linton. 2000. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Arterioscler. Thromb. Vasc. Biol. 20: 2593-2599.
68. Kunjathoor, V. V., M. Febbraio, E. A. Podrez, K. J. Moore, L. Andersson, S. Koehn, J. S. Rhee, R. Silverstein, H. F. Hoff, and M. W. Freeman. 2002. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277: 49982-49988.
69. Nakagawa-Toyama, Y., S. Yamashita, J. Miyagawa, M. Nishida, S. Nozaki, H. Nagaretani, N. Sakai, H. Hiraoka, K. Yamamori, T. Yamane, K. Hirano, and Y. Matsuzawa. 2001. Localization of CD36 and scavenger receptor class A in human coronary arteries - a possible difference in the contribution of both receptors to plaque formation. Atherosclerosis. 156: 297-305.
70. Hampton, R. Y., D. T. Golenbock, M. Penman, M. Krieger, and C. R. Raetz. 1991. Recognition and plasma clearance of endotoxin by scavenger receptors. Nature. 352: 342-344.
71. Haworth, R., N. Platt, S. Keshav, D. Hughes, E. Darley, H. Suzuki, Y. Kurihara, T. Kodama, and S. Gordon. 1997. The macrophage scavenger receptor type A is expressed by activated macrophages and protects the host against lethal endotoxic shock. J. Exp. Med. 186: 1431-1439.
72. Thomas, C. A., Y. Li, T. Kodama, H. Suzuki, S. C. Silverstein, and J. El Khoury. 2000. Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent phagocytosis. J. Exp. Med. 191: 147-156.
73. Peiser, L., M. P. De Winther, K. Makepeace, M. Hollinshead, P. Coull, J. Plested, T. Kodama, E. R. Moxon, and S. Gordon. 2002. The class A macrophage scavenger receptor is a major pattern recognition receptor for Neisseria meningitidis which is independent of lipopolysaccharide and not required for secretory responses. Infect. Immun. 70: 5346-5354.
74. Mukhopadhyay, S., L. Peiser, and S. Gordon. 2004. Activation of murine macrophages by Neisseria meningitidis and IFN-gamma in vitro: distinct roles of class A scavenger and Toll-like pattern recognition receptors in selective modulation of surface phenotype. J. Leukoc. Biol. 76: 577-584.
75. Harshyne, L. A., M. I. Zimmer, S. C. Watkins, and S. M. Barratt-Boyes. 2003. A role for class A scavenger receptor in dendritic cell nibbling from live cells. J. Immunol. 170: 2302-2309.
76. Elomaa, O., M. Kangas, C. Sahlberg, J. Tuukkanen, R. Sormunen, A. Liakka, I. Thesleff, G. Kraal, and K. Tryggvason. 1995. Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages. Cell 80: 603-609.
77. Brannstrom, A., M. Sankala, K. Tryggvason, and T. Pikkarainen. 2002. Arginine residues in domain V have a central role for bacteria-binding activity of macrophage scavenger receptor MARCO. Biochem. Biophys. Res. Commun. 290: 1462-1469.
78. Acton, S., D. Resnick, M. Freeman, Y. Ekkel, J. Ashkenas, and M. Krieger. 1993. The collagenous domains of macrophage scavenger receptors and complement component C1q mediate their similar, but not identical, binding specificities for polyanionic ligands. J. Biol. Chem. 268: 3530-3537.
79. Doi, T., K. Higashino, Y. Kurihara, Y. Wada, T. Miyazaki, H. Nakamura, S. Uesugi, T. Imanishi, Y. Kawabe, and H. Itakura. 1993. Charged collagen structure mediates the recognition of negatively charged macromolecules by macrophage scavenger receptors. J. Biol. Chem. 268: 2126-2133.
80. Arredouani, M., Z. Yang, Y. Ning, G. Qin, R. Soininen, K. Tryggvason, and L. Kobzik. 2004. The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles. J. Exp. Med. 200: 267-272.
81. da Silva, R. P., N. Platt, J. S. de Villiers, and S. Gordon. 1996. Membrane molecules and macrophage endocytosis: scavenger receptor and macrosialin as markers of plasma-membrane and vacuolar functions. Biochem. Soc. Trans. 24: 220-224.
82. Holness, C. L., R. P. da Silva, J. Fawcett, S. Gordon, and D. L. Simmons. 1993. Macrosialin, a mouse macrophage-restricted glycoprotein, is a member of the lamp/lgp family. J. Biol. Chem. 268: 9661-9666.
83. Ramprasad, M. P., V. Terpstra, N. Kondratenko, O. Quehenberger, and D. Steinberg. 1996. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA. 93: 14833-14838.
84. Ramprasad, M. P., W. Fischer, J. L. Witztum, G. R. Sambrano, O. Quehenberger, and D. Steinberg. 1995. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc. Natl. Acad. Sci. USA. 92: 9580-9584.
85. Van Velzen, A. G., R. P. Da Silva, S. Gordon, and T. J. Van Berkel. 1997. Characterization of a receptor for oxidized low-density lipoproteins on rat Kupffer cells: similarity to macrosialin. Biochem. J. 322 (Pt 2): 411-415.
86. Sawamura, T., N. Kume, T. Aoyama, H. Moriwaki, H. Hoshikawa, Y. Aiba, T. Tanaka, S. Miwa, Y. Katsura, T. Kita, and T. Masaki. 1997. An endothelial receptor for oxidized low-density lipoprotein. Nature. 386: 73-77.
87. Kataoka, H., N. Kume, S. Miyamoto, M. Minami, T. Murase, T. Sawamura, T. Masaki, N. Hashimoto, and T. Kita. 2000. Biosynthesis and post-translational processing of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1). N-linked glycosylation affects cell-surface expression and ligand binding. J. Biol. Chem. 275: 6573-6579.
88. Xie, Q., S. Matsunaga, S. Niimi, S. Ogawa, K. Tokuyasu, Y. Sakakibara, and S. Machida. 2004. Human lectin-like oxidized low-density lipoprotein receptor-1 functions as a dimer in living cells. DNA Cell Biol. 23: 111-117.
89. Murase, T., N. Kume, H. Kataoka, M. Minami, T. Sawamura, T. Masaki, and T. Kita. 2000. Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler. Thromb. Vasc. Biol. 20: 715-720.
90. Moriwaki, H., N. Kume, T. Sawamura, T. Aoyama, H. Hoshikawa, H. Ochi, E. Nishi, T. Masaki, and T. Kita. 1998. Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 18: 1541-1547.
91. Kume, N., and T. Kita. 2001. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in atherogenesis. Trends Cardiovasc. Med. 11: 22-25.
92. Chen, M., T. Masaki, and T. Sawamura. 2002. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol. Ther. 95: 89-100.
93. Moriwaki, H., N. Kume, H. Kataoka, T. Murase, E. Nishi, T. Sawamura, T. Masaki, and T. Kita. 1998. Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-alpha. FEBS Lett. 440: 29-32.
94. Kataoka, H., N. Kume, S. Miyamoto, M. Minami, H. Moriwaki, T. Murase, T. Sawamura, T. Masaki, N. Hashimoto, and T. Kita. 1999. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation. 99: 3110-3117.
95. Shimaoka, T., N. Kume, M. Minami, K. Hayashida, H. Kataoka, T. Kita, and S. Yonehara. 2000. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J. Biol. Chem. 275: 40663-40666.
96. Hofnagel, O., B. Luechtenborg, G. Plenz, and H. Robenek. 2002. Expression of the novel scavenger receptor SR-PSOX in cultured aortic smooth muscle cells and umbilical endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22: 710-711.
97. Matloubian, M., A. David, S. Engel, J. E. Ryan, and J. G. Cyster. 2000. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat. Immunol. 1: 298-304.
98. Shimaoka, T., T. Nakayama, N. Kume, S. Takahashi, J. Yamaguchi, M. Minami, K. Hayashida, T. Kita, J. Ohsumi, O. Yoshie, and S. Yonehara. 2003. Cutting Edge. SR-PSOX/CXC chemokine ligand 16 mediates bacterial phagocytosis by APCs through its chemokine domain. J. Immunol. 171: 1647-1651.
99. Shimaoka, T., T. Nakayama, K. Hieshima, N. Kume, N. Fukumoto, M. Minami, K. Hayashida, T. Kita, O. Yoshie, and S. Yonehara. 2004. Chemokines generally exhibit scavenger receptor activity through their receptor-binding domain. J. Biol. Chem. 279: 26807-26810.
100. Minami, M., N. Kume, T. Shimaoka, H. Kataoka, K. Hayashida, Y. Akiyama, I. Nagata, K. Ando, M. Nobuyoshi, M. Hanyuu, M. Komeda, S. Yonehara, and T. Kita. 2001. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 21: 1796-1800.
101. Wuttge, D. M., X. Zhou, Y. Sheikine, D. Wagsater, V. Stemme, U. Hedin, S. Stemme, G. K. Hansson, and A. Sirsjo. 2004. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 24: 750-755.
102. Adachi, H., M. Tsujimoto, H. Arai, and K. Inoue. 1997. Expression cloning of a novel scavenger receptor from human endothelial cells. J. Biol. Chem. 272: 31217-31220.
103. Adachi, H., and M. Tsujimoto. 2002. FEEL-1, a novel scavenger receptor with in vitro bacteria-binding and angiogenesis-modulating activities. J. Biol. Chem. 277: 34264-34270.
104. Politz, O., A. Gratchev, P. A. McCourt, K. Schledzewski, P. Guillot, S. Johansson, G. Svineng, P. Franke, C. Kannicht, J. Kzhyshkowska, P. Longati, F. W. Veiten, and S. Goerdt. 2002. Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues. Biochem. J. 362: 155-164.
105. Kzhyshkowska, J., A. Gratchev, J. H. Martens, O. Pervushina, S. Mamidi, S. Johansson, K. Schledzewski, B. Hansen, X. He, J. Tang, K. Nakayama, and S. Goerdt. 2004. Stabilin-1 localizes to endosomes and the trans-Golgi network in human macrophages and interacts with GGA adaptors. J. Leukoc. Biol. In press.
106. Tamura, Y., H. Adachi, J. Osuga, K. Ohashi, N. Yahagi, M. Sekiya, H. Okazaki, S. Tomita, Y. Iizuka, H. Shimano, R. Nagai, S. Kimura, M. Tsujimoto, and S. Ishibashi. 2003. FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J. Biol. Chem. 278: 12613-12617.
107. Tamura, Y., J. Osuga, H. Adachi, R. Tozawa, Y. Takanezawa, K. Ohashi, N. Yahagi, M. Sekiya, H. Okazaki, S. Tomita, Y. Iizuka, H. Koizumi, T. Inaba, H. Yagyu, N. Kamada, H. Suzuki, H. Shimano, T. Kadowaki, M. Tsujimoto, H. Arai, N. Yamada, and S. Ishibashi. 2004. Scavenger receptor expressed by endothelial cells I (SREC-I) mediates the uptake of acetylated low density lipoproteins by macrophages stimulated with lipopolysaccharide. J. Biol. Chem. 279: 30938-30944.
108. Berwin, B., Y. Delneste, R. V. Lovingood, S. R. Post, and S. V. Pizzo. 2004. SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin. J. Biol. Chem. In press.
109. Shibata, M., J. Ishii, H. Koizumi, N. Shibata, N. Dohmae, K. Takio, H. Adachi, M. Tsujimoto, and H. Arai. 2004. Type F scavenger receptor SREC-I interacts with advillin, a member of the gelsolin/villin family, and induces neurite-like outgrowth. J. Biol. Chem. 279: 40084-40090.
110. Kristiansen, M., J. H. Graversen, C. Jacobsen, O. Sonne, H. J. Hoffman, S. K. Law, and S. K. Moestrup. 2001. Identiucation of the haemoglobin scavenger receptor. Nature. 409: 198-201.
111. Matsushita, N., M. Kashiwagi, R. Wait, R. Nagayoshi, M. Nakamura, T. Matsuda, P. Hogger, P. M. Guyre, H. Nagase, and T. Matsuyama. 2002. Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin. Exp. Immunol. 130: 156-161.
112. Asleh, R., S. Marsh, M. Shilkrut, O. Binah, J. Guetta, F. Lejbkowicz, B. Enav, N. Shehadeh, Y. Kanter, O. Lache, O. Cohen, N. S. Levy, and A. P. Levy. 2003. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ. Res. 92: 1193-1200.
113. Fadok, V. A., D. L. Bratton, D. M. Rose, A. Pearson, R. A. Ezekewitz, and P. M. Henson. 2000. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature. 405: 85-90.
114. Bose, J., A. D. Gruber, L. Helming, S. Schiebe, I. Wegener, M. Hafner, M. Beales, F. Kontgen, and A. Lengeling. 2004. The phosphatidylserine receptor has essential functions during embryogenesis but not in apoptotic cell removal. J. Biol. 3: 15.
115. Medzhitov, R., and C. Janeway, Jr. 2000. Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173: 89-97.
116. Shaw, P. X., S. Horkko, M. K. Chang, L. K. Curtiss, W. Palinski, G. J. Silverman, and J. L. Witztum. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105: 1731-1740.
117. Kedzierski, L., J. Montgomery, D. Bullen, J. Curtis, E. Gardiner, A. Jimenez-Ruiz, and E. Handman. 2004. A leucine-rich repeat motif of Leishmania parasite surface antigen 2 binds to macrophages through the complement receptor 3. J. Immunol. 172: 4902-4906.
118. Bajtay, Z., C. Speth, A. Erdei, and M. P. Dierich. 2004. Cutting Edge. Productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18). J. Immunol. 173: 4775-4778.
119. Rosenson, R. S., and A. S. Brown. 2002. Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence. Curr. Opin. Lipidol. 13: 625-630.
120. Fuhrman, B., L. Koren, N. Volkova, S. Keidar, T. Hayek, and M. Aviram. 2002. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis. 164: 179-185.
121. Azen, S. P., D. Qian, W. J. Mack, A. Sevanian, R. H. Selzer, C. R. Liu, C. H. Liu, and H. N. Hodis. 1996. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation. 94: 2369-2372.
122. Steinberg, D. 2000. Is there a potential therapeutic role for vitamin E or other antioxidants in atherosclerosis? Curr. Opin. Lipidol. 11: 603-607.
123. Boaz, M., S. Smetana, T. Weinstein, Z. Matas, U. Gafter, A. Iaina, A. Knecht, Y. Weissgarten, D. Brunner, M. Fainaru, and M. S. Green. 2000. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 356: 1213-1218.
124. Wickelgren, I. 2004. Heart disease. Gene suggests asthma drugs may ease cardiovascular inflammation. Science. 303: 941.
125. Weisberg, S. P., D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante, Jr. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112: 1796-1808.
126. Prevo, R., S. Banerji, J. Ni, and D. G. Jackson. 2004. Rapid plasma membrane-endosomal trafficking of the lymph node sinus and high endothelial venule scavenger receptor/homing receptor stabilin-1 (FEEL-1/CLEVER-1). J. Biol. Chem. In press.
127. El Khoury, J. B., K. J. Moore, T. K. Means, J. Leung, K. Terada, M. Toft, M. W. Freeman, and A. D. Luster. 2003. CD36 mediates the innate host response to beta-amyloid. J. Exp. Med. 197: 1657-1666.
128. Geissmann, F., S. Jung, and D. R. Littman. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 19: 71-82.
129. Taylor, P. R., and S. Gordon. 2003. Monocyte heterogeneity and innate immunity. Immunity. 19: 2-4.